Debt-to-equity of Lyra Therapeutics, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lyra Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Lyra Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 1616%, a 1378% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Lyra Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 1616% +1507% +1378% 30 Sep 2025
Q2 2025 574% +497% +645% 30 Jun 2025
Q1 2025 341% +290% +561% 31 Mar 2025
Q4 2024 171% +128% +301% 31 Dec 2024
Q3 2024 109% +73% +199% 30 Sep 2024
Q2 2024 77% +44% +136% 30 Jun 2024
Q1 2024 52% +21% +67% 31 Mar 2024
Q4 2023 43% +9% +25% 31 Dec 2023
Q3 2023 37% 0% -0.82% 30 Sep 2023
Q2 2023 33% -10% -23% 30 Jun 2023
Q1 2023 31% -21% -40% 31 Mar 2023
Q4 2022 34% +2% +7.7% 31 Dec 2022
Q3 2022 37% +16% +78% 30 Sep 2022
Q2 2022 42% +29% +220% 30 Jun 2022
Q1 2022 52% +44% +568% 31 Mar 2022
Q4 2021 32% +9% +40% 31 Dec 2021
Q3 2021 21% +54% 30 Sep 2021
Q2 2021 13% 30 Jun 2021
Q1 2021 8% 31 Mar 2021
Q4 2020 23% 31 Dec 2020
Q3 2020 -33% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.